Longevity of daily oral Vitamin D3 supplementation:Differences in 25OHD and 24,25(OH)2D observed 2 years after cessation of a 1-year randomized controlled trial (VICtORy RECALL)

Macdonald, H. M., Gryka, A., Tang, J. C. Y., Aucott, L. S., Fraser, W. D. and Wood, A. D. (2017) Longevity of daily oral Vitamin D3 supplementation:Differences in 25OHD and 24,25(OH)2D observed 2 years after cessation of a 1-year randomized controlled trial (VICtORy RECALL). Osteoporosis International, 28 (12). 3361–3372. ISSN 0937-941X

Preview

PDF (Accepted manuscript) - Accepted Version Available under License Unspecified licence. Download (515kB) | Preview

Abstract

Purpose To determine the longevity of vitamin D status following cessation of vitamin D3 supplementation, 2 and 3 years after a 1 year randomised double blind placebo controlled trial: (Vitamin D and Cardiovascular Risk (VICtORY)); and to investigate possible predictive factors. Method Of the 305 Caucasian non-smoking postmenopausal women randomised to ViCtORY (2009-2010), participants who had not taken vitamin D supplements since the trial ended were invited to attend follow up visits. Total 25-hydroxyvitamin D (25OHD) and 24,25-dihydroxyvitamin D (24,25OH2D) were measured by dual tandem mass spectrometry of serum samples following removal of protein and de-lipidation; the original RCT samples were re-analysed simultaneously. Vitamin D binding protein (VDBP) was measured by monoclonal immunoassay. Results In March 2012 and March 2013, 159 women (mean (SD) age 67.6 (2.1) years) re-attended, distributed between the original treatment groups: daily vitamin D3 400IU; 1000IU; and placebo. One month after the RCT ended (March 2010) the proportion of women in placebo, 400IU, and 1000IU vitamin D3 groups, respectively, with 25OHD<25 nmol/ L was 15%,0%, 0% (Chi-square p<0.001, n=46,44,54). After 2 years (March 2012) it was 22%, 4%, 4% (p=0.002, n=50,48,57); after 3 years 23%, 13%, 15% (p=0.429,n=48,45,52). The respective proportion of women with 24,25OH2D < 2.2 nmol/L were 50%, 2%, 2% (1 month, p>0.001, n=46,44,54); 42%, 33%, 12% (2y, p=0.002,n=50,48,57) and 45%, 27%, 29% (3y, p=0.138, n=47,45,51,). VDBP was a predictor of circulating 25OHD longevity (beta for VDBP in µg/ml:0.736; 95% CI 0.216-1.255,p=0.006) but not 24,25OH2D.

Item Type:	Article
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Musculoskeletal Medicine Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Depositing User:	Pure Connector
Date Deposited:	25 Aug 2017 05:07
Last Modified:	06 Feb 2025 07:24
URI:	https://ueaeprints.uea.ac.uk/id/eprint/64670
DOI:	10.1007/s00198-017-4201-2

Downloads

Actions (login required)

View Item